Mode of Action, In Vitro Activity, and In Vivo Efficacy of AFN-1252, a Selective Antistaphylococcal FabI Inhibitor

Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit StumbleUpon Twitter current issue AAC About AAC Subscribers Authors Reviewers Advertisers Inquiries from the Press Permissions & Commerc...

Full description

Saved in:
Bibliographic Details
Published inAntimicrobial Agents and Chemotherapy Vol. 56; no. 11; pp. 5865 - 5874
Main Authors KAPLAN, Nachum, ALBERT, Monique, SCHMID, Molly B, THALAKADA, Rosanne, YETHON, Jeremy, PAULS, Henry W, AWREY, Donald, BARDOUNIOTIS, Elias, BERMAN, Judd, CLARKE, Teresa, DORSEY, Mandy, HAFKIN, Barry, RAMNAUTH, Jaillal, ROMANOV, Vladimir
Format Journal Article
LanguageEnglish
Published Washington, DC American Society for Microbiology 01.11.2012
Subjects
Administration, Oral
Animals
Anti-Bacterial Agents
Anti-Bacterial Agents - pharmacology
Anti-Bacterial Agents - therapeutic use
Antibiotics. Antiinfectious agents. Antiparasitic agents
Bacterial Proteins
Bacterial Proteins - antagonists & inhibitors
Bacterial Proteins - metabolism
Benzofurans
Benzofurans - pharmacology
Benzofurans - therapeutic use
Biological and medical sciences
Community-Acquired Infections - drug therapy
Community-Acquired Infections - microbiology
Cross Infection - drug therapy
Cross Infection - microbiology
Drug Administration Schedule
Enoyl-(Acyl-Carrier-Protein) Reductase (NADH)
Enoyl-(Acyl-Carrier-Protein) Reductase (NADH) - antagonists & inhibitors
Enoyl-(Acyl-Carrier-Protein) Reductase (NADH) - metabolism
Female
Humans
Kinetics
Mechanisms of Action: Physiological Effects
Medical sciences
Mice
Microbial Sensitivity Tests
Pharmacology. Drug treatments
Pyrones
Pyrones - pharmacology
Pyrones - therapeutic use
Sepsis
Sepsis - drug therapy
Sepsis - microbiology
Sepsis - mortality
Staphylococcal Infections
Staphylococcal Infections - drug therapy
Staphylococcal Infections - microbiology
Staphylococcus aureus
Staphylococcus aureus - drug effects
Staphylococcus aureus - enzymology
Staphylococcus aureus - growth & development
Survival Rate
In vivo
Inhibitor
Mechanism of action
In vitro
Treatment efficiency
Biological activity
Online AccessGet full text

Cover

More Information
Summary:Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit StumbleUpon Twitter current issue AAC About AAC Subscribers Authors Reviewers Advertisers Inquiries from the Press Permissions & Commercial Reprints ASM Journals Public Access Policy AAC RSS Feeds 1752 N Street N.W. • Washington DC 20036 202.737.3600 • 202.942.9355 fax • journals@asmusa.org Print ISSN: 0066-4804 Online ISSN: 1098-6596 Copyright © 2014 by the American Society for Microbiology.   For an alternate route to AAC .asm.org, visit: AAC       
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Present address: Monique Albert, MaRs Discovery District, Toronto, ON, Canada; Donald Awrey, Campbell Family Institute for Breast Cancer Research, TMDT, Toronto, ON, Canada; Elias Bardouniotis, Switzerland Trade and Investment Promotion, Toronto, ON, Canada; Judd Berman, Dalton Medicinal Chemistry, Toronto, ON, Canada; Teresa Clarke, Ontario Genomics Institute, Toronto, ON, Canada; Mandy Dorsey, OptumInsight, Dundas, ON, Canada; Barry Hafkin, Affinium Pharmaceuticals, Ltd., Austin, Texas, USA; Jaillal Ramnauth, NeurAxon Inc., Mississauga, ON, Canada; Vladimir Romanov, Ontario Cancer Institute, Princess Margaret Hospital, Toronto, ON, Canada; Molly B. Schmid, NeoPrl Therapeutics, Claremont, California, USA; Rosanne Thalakada, Leslie L. Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada; Jeremy Yethon, Sanofi Pasteur, Cambridge, Massachusetts, USA.
ISSN:0066-4804
1098-6596
DOI:10.1128/AAC.01411-12